Clinical Trial Applications: Filter, Search, and view applications
| # | Protocol No | Study Title | Investigator(s) & Site(s) | |
|---|---|---|---|---|
351. |
ECCT/17/08/01 | A trial to compare the safety and immune response of the normal full and reduced doses of yellow fever vaccines in Kenyan adults A Phase IV randomized, double blinded non-inferiority trial on the immunogenicity and safety of fractional doses of yellow fever vaccines. |
Principal Investigator(s) 1. Philip Bejon Site(s) in Kenya KEMRI Kilifi |
View |
352. |
ECCT/17/07/01 | ABCD Antibiotics for Children with Severe Diarrhea Trial |
Principal Investigator(s) 1. Judd Walson Site(s) in Kenya 1. Rongo Sub-County Hospital (Migori county) 2. Ndhiwa Sub-County Hospital (Homa Bay county) 3. Rachuonyo Sub-County Hospital (Homa Bay county) 4. Isebania Sub-County Hospital (Migori county) 5. Awendo Sub-County Hospital (Migori county) 6. Mbita Sub-County Hospital (Homa Bay county) |
View |
353. |
ECCT/17/06/02 | PAINT Study A Phase II, open label, single arm trial to evaluate the pharmacokinetics, safety, tolerability, and antiviral activity of rilpivirine (TMC278) in antiretroviral-naïve HIV-1 infected adolescents and children aged ≥6 to <18 years |
Principal Investigator(s) 1. Isaac Tsikhutsu Site(s) in Kenya 1. Kenya Medical Research Institute/Walter Reed Project, HIV Program (Kericho county) 2. KAVI Institute of Clinical Research (Nairobi City county) |
View |
354. |
ECCT/17/06/01 | MF/PM Phase III An Open Label, Phase III, Randomized Controlled, Multicentre Non-Inferiority Trial to Compare Efficacy and Safety of Miltefosine and Paromomycin with Sodium Stibogluconate and Paromomycin Combination for Treatment of Primary Visceral Leishmaniasis (VL) Patients in Eastern Africa |
Principal Investigator(s) 1. Jane Mbui Site(s) in Kenya 1. Kimalel Health Centre (Baringo county) 2. Kacheliba sub-county hospital (West Pokot county) |
View |
355. |
ECCT/17/05/04 | Ad26.Mos4.HIV Prime/Ad26.Mos4.HIV with Clade C gp140 plus adjuvant +/- Mosaic boost A randomized, parallel-group, placebo-controlled, double-blind Phase 1/2a study in healthy HIV-uninfected adults to assess safety/tolerability and immunogenicity of 2 different prime/boost regimens: priming with tetravalent Ad26.Mos4.HIV and boosting with tetravalent Ad26.Mos4.HIV and either Clade C gp140 plus adjuvant OR a combination of Mosaic and Clade C gp140 plus adjuvant |
Principal Investigator(s) 1. Josphat Kosgei Site(s) in Kenya KEMRI WALTER REED KERICHO |
View |